Compare GDV & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDV | WVE |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | N/A | 2015 |
| Metric | GDV | WVE |
|---|---|---|
| Price | $27.60 | $13.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $30.87 |
| AVG Volume (30 Days) | 126.0K | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 5.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $119.93 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $20.10 | $5.28 |
| 52 Week High | $29.46 | $21.73 |
| Indicator | GDV | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 27.47 | 47.06 |
| Support Level | $26.26 | $12.53 |
| Resistance Level | $28.85 | $14.56 |
| Average True Range (ATR) | 0.38 | 0.79 |
| MACD | -0.19 | -0.04 |
| Stochastic Oscillator | 20.98 | 26.10 |
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.